This figure shows the analytic framework of this report. In patients with epilepsy and relevant subgroups based upon gender, age, baseline clinical status, and prior therapy, we seek to answer the effect that antiepileptic medications may have. The first step in the analytic framework deals with intermediate outcomes from antiepileptic medications, which includes maximal concentrations, minimal concentrations at steady state, average steady state concentrations, area under the curve, dose needed to control seizure, switchback rate from generic to innovator antiepileptic medication. Final health outcomes can either be answered from the direct evidence that exists in epilepsy patients treated with antiepileptic medications or by assessing the link between intermediate and final health outcomes (which include mortality, hospitalization, office/emergency department visits, composite of ambulance services, hospitalization, or emergency department visits for epilepsy, health-related quality-of-life, time to first seizure, time to exit due to lack of efficacy, proportion of seizure free patients, proportion of patients completing the study, proportion of patients with seizure remission, breakthrough seizures, seizure frequency reduction, secondary seizure injury, status epilepticus, loss of driver's license, or loss of employment). Adverse events associated with antiepileptic medication use are also evaluated, including total adverse events, neurological adverse events, hypotension, rash, suicidal ideation, mood and cognition, bone density, or cosmetic adverse effects.

Figure 1Analytic framework for the evaluation of effectiveness and safety of antiepileptic medication in patients with epilepsy

KQ = Key Question

From: Introduction

Cover of Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy
Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy [Internet].
Comparative Effectiveness Reviews, No. 40.
Talati R, Scholle JM, Phung OJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.